Dr. Peter Rost: " We didn't discover drugs, we discovered markets. If a drug cured asthma in 3 days, we would eliminate it.
Chronic diseases are where the money is. Cures are bad for business."
Microsoft's CoPilot confirms the above quote thus:“'If a drug cured asthma in 3 days, we'd kill it. Chronic disease is where the money is. Cures are bad for business'...
While some debate the literal interpretation of this claim, it underscores the broader concern that financial incentives in the pharmaceutical industry may not always align with optimal patient outcomes. Overall, Rost’s perspective provides insight into the ethical and economic dynamics of the pharmaceutical industry, illustrating why whistleblowers and regulatory oversight are considered crucial for accountability and patient safety.
CoPilot adds:"Peter Rost, former Pfizer executive, claimed that pharmaceutical companies often prioritize market creation over curing diseases, asserting that chronic conditions are more profitable than cures.Peter Rost is an American former drug marketing executive who worked at Pfizer and other pharmaceutical companies for many years, gaining insider knowledge of industry practices He became widely known for his whistleblower activities, particularly exposing off-label marketing of drugs like Genotropin and other unethical practices within Pfizer and Pharmacia
Rost has publicly stated that during his tenure, the focus was often on discovering markets rather than drugs themselves, and that cures for diseases could be seen as financially disadvantageous because chronic conditions generate ongoing revenue.
In his book, The Whistleblower: Confessions of a Healthcare Hitman, Rost details how he observed and challenged practices such as off-label marketing, channel stuffing, and prioritizing profit over patient outcomes.He emphasizes that the pharmaceutical business model can create incentives that favor long-term treatment over outright cures, raising ethical concerns about patient care and transparency."
